




A




B



C




D




Supplementary Figure 1. Related to Figure 1; *HOTTIP* loss led to inhibition of posterior HOXA genes and other genes critical for hematopoiesis and leukemogenesis (A) PCR based genotyping and Sanger sequencing confirmation of two CRISPR-Cas9 mediated *HOTTIP*^{-/-} clones in MOLM13 cells. **(B)** Enrichment of downregulated target genes involved in NOTCH signaling and cell adhesion/migration pathways in the *HOTTIP*^{-/-} clones compared to WT control as shown by GSEA. **(C)** Overlap between differentially expressed genes by comparing RNA-seq data obtained from the *HOTTIP*^{-/-} and the CBS7/9 boundary attenuated MOLM13 cells. **(D)** RT-qPCR validation of the key altered hematopoietic/leukemic genes identified by RNA-seq analysis of the WT control and two *HOTTIP*^{-/-} clones. Data is presented as mean ± SD from three or four independent experiments; *p<0.05; **p<0.01 by Student's t-test.


A




B



Supplementary Figure 2. Related to Figure 2; *HOTTIP* is aberrantly expressed in AML patients and cell lines. (A) Expression of *HOTTIP* in normal healthy individual, MLL rearranged AML cell lines and patients by RT-qPCR. Data represents mean \pm SD from three independent experiments. (B) Expression of *HOTTIP* in MOLM13, OCI-AML3 and OCI-AML2 cells determined by RT-PCR or RT-qPCR.





Supplementary Figure 3. Related to Figure 3; Deletion of *HOTTIP* in AML cells perturbs its binding to chromatin as well as target gene chromatin structure and accessibility. (A) RT-qPCR analysis of RNA retrieved by the complementary *HOTTIP*-tiling probes and *lacZ* probes compared WT and *HOTTIP*^{-/-} MOLM13 cells. Error bars show mean \pm SD from three to four independent experiments; * $p < 0.05$; ** $p < 0.01$ by Student's t-test. **(B)** ChIRP-qPCR analysis of the *HOTTIP* RNA enrichment at the *HOXA* locus compared WT and *HOTTIP*^{-/-} MOLM13 cells. Error bars show mean \pm SD from three to four independent experiments; * $p < 0.05$; ** $p < 0.01$ by Student's t-test. **(C)** ChIRP-seq analysis of *HOTTIP* lncRNA binding in the *HOXB* locus compared WT and *HOTTIP*^{-/-} MOLM13 cells. **(D)** The genes and pathways regulated by the *HOTTIP* bound intergenic regions were analyzed and annotated by the Gene Ontology analysis. **(E)** Alterations in *HOTTIP* binding (ChIRP-seq), chromatin accessibility (ATAC-seq), MLL1 recruitment and H3K4me3 enrichment (ChIP-seq) in the *HOTTIP* *trans* regulated genes, *RUNX1*, *MEIS2*, and *TWIST1*, compared WT and *HOTTIP* KO MOLM13 cells. P1: promoter 1 of *RUNX1*; P2: promoter 2 of *RUNX1*. **(F)** RT-qPCR analysis of *HOTTIP* RNA retrieved by antibodies against RUNX1, WDR5, MLL1, MYC, and p-STAT5A precipitated from the MOLM13 nuclear extract. **(G)** ChIP-seq analysis of changes in H3K4me3, H3K27me3, and H3K79me2 modification levels in the *HOXB* locus in the MOLM13 cells compared with the WT and the *HOTTIP*^{-/-}. **(H)** ATAC-seq analysis of changes in chromatin accessibility upon *HOTTIP*^{-/-} in MOLM13 cells. Shown are altered promoter chromatin accessibility in the *HOXB* locus.

Table S1: Transcription factor bound Motifs analyzed and annotated using ChIRP-seq and ATAC-seq datasets. Related to Figure 3.

ATAC associated			HOTTIP-CHIRP	
Motif	p value		Motif	p value
ETS1	1.00E-465		E-box	1.00E-658
CTCF	1.00E-341		CRE	1.00E-520
E-Box	1.00E-265		RUNX1	1.00E-467
CRE	1.00E-231		HOXA13	1.00E-360
RUNX1	1.00E-215		c-Myc	1.00E-320
c-Myc	1.00E-180		MEIS1	1.00E-280
Max	1.00E-139		USF1	1.00E-259
STAT5	1.00E-122		CTCF	1.00E-220
USF1	1.00E-118		Max	1.00E-215
E2F	1.00E-98		STAT5	1.00E-142
STAT1	1.00E-87		TEAD4	1.00E-120
PU.1	1.00E-81		Smad3	1.00E-101
STAT3	1.00E-70		SOX9	1.00E-91
Nanog	1.00E-49		HLF	1.00E-78
YY1	1.00E-35		MYB	1.00E-69
ATF3	1.00E-22		CDX4	1.00E-60
FOXA1	1.00E-18		ELF4	1.00E-48
SP2	1.00E-14		USF2	1.00E-36
ATF1	1.00E-12		STAT1	1.00E-27
FLI1	1.00E-10		PU.1	1.00E-16
KLF6	1.00E-08		TCF12	1.00E-10
MYB	1.00E-08		Tbx20	1.00E-09
NFAT	1.00E-07		ERG	1.00E-08
ELF4	1.00E-06		TCF4	1.00E-07
TBX5	1.00E-05		AP1	1.00E-07
E2A	1.00E-05		LHX1	1.00E-06
TCF4	1.00E-05		ATF1	1.00E-05
			FRA1	1.00E-05

Table S2: Statistical analysis of ATAC differential peaks and p value. Related to Figures 3, 5 and 8.


Ctrl vs <i>HOTTIP</i>^{-/-}					
Chr	start	end	log2FoldChange (Ctrl vs KO)	Adj p value	Genes
chr7	27239961	27240137	2.653	3.28E-13	<i>HOTTIP</i>
chr7	27200117	27201441	2.385	1.45E-08	<i>HOXA9</i>
chr7	27239593	27240001	1.917	1.58E-10	<i>HOXA13</i>
chr21	36260643	36261680	1.614	5.63E-06	<i>RUNX1</i>
chr17	40440299	40440741	1.445	1.72E-08	<i>STAT5A</i>
chr8	128747648	128748815	1.411	3.61E-06	<i>MYC</i>
chr7	27219354	27220019	1.395	4.17E-05	<i>HOXA10</i>
chr7	27224552	27225091	1.378	3.63E-05	<i>HOXA11</i>
chr19	51728058	51728855	1.356	4.11E-06	<i>CD33</i>
chr7	19156515	19157393	1.346	5.20E-08	<i>TWIST1</i>
chr15	37393235	37393784	1.338	5.19E-05	<i>MEIS2</i>
chr9	128509129	128509991	1.327	3.45E-06	<i>PBX3</i>
chr4	55523944	55524288	1.214	7.64E-07	<i>KIT</i>





<i>HOTTIP</i>-VP vs <i>CBS7/9</i>^{+/-}					
Chr	start	end	log2FoldChange (VP vs KO)	Adj p value	Genes
chr7	27239612	27239999	2.882	5.56E-17	<i>HOXA13</i>
chr7	27239945	27240143	2.265	3.51E-16	<i>HOTTIP</i>
chr21	36260648	36261668	1.831	8.35E-10	<i>RUNX1</i>
chr15	37393239	37393779	1.776	6.44E-09	<i>MES12</i>
chr7	19156523	19157390	1.482	1.08E-07	<i>TWIST1</i>
chr2	239756363	239757156	1.387	1.01E-06	<i>TWIST2</i>
chr2	66662301	66663195	1.352	1.98E-05	<i>MEIS1</i>
chr7	27200112	27201446	1.323	2.04E-09	<i>HOXA9</i>
chr17	40440313	40440733	1.302	5.33E-07	<i>STAT5A</i>
chr8	128747661	128748802	1.281	6.43E-07	<i>MYC</i>
chr2	145277521	145278173	1.256	4.11E-06	<i>ZEB2</i>
chr9	128509121	128510008	1.245	8.97E-05	<i>PBX3</i>
chr7	27219332	27220028	1.230	5.34E-06	<i>HOXA10</i>
chr7	27224556	27225095	1.202	7.95E-05	<i>HOXA11</i>
chr11	128391555	128392392	1.198	5.49E-06	<i>ETS1</i>

Continued

Hottip-Tg vs Ctrl LT-HSC					
Chr	start	end	log2FoldChange (HT vs Ctrl)	Adj p value	Genes
chr6	52212340	52213115	2.268	6.89E-21	<i>Hottip</i>
chr6	52172626	52173303	2.090	1.21E-20	<i>Hoxa9</i>
chr6	52209155	52210718	1.971	3.35E-19	<i>Hoxa13</i>
chr16	92826082	92826426	1.789	1.21E-16	<i>Runx1</i>
chr6	52189793	52191345	1.747	2.26E-18	<i>Hoxa10</i>
chr2	34227091	34227906	1.521	6.48E-12	<i>Pbx3</i>
chr11	18918453	18919407	1.342	6.48E-10	<i>Meis1</i>
chr15	61816553	61817375	1.267	3.26E-13	<i>Myc</i>
chr12	34642150	34643195	1.204	3.42E-09	<i>Twist1</i>
chr6	52195231	52196121	1.145	4.98E-07	<i>Hoxa11</i>


Hottip-Tg vs Ctrl ST-HSC					
Chr	start	end	log2FoldChange(HT vs Ctrl)	Adj p value	Genes
chr6	52212348	52213124	2.395	1.18E-28	<i>Hottip</i>
chr6	52172626	52173303	1.805	4.33E-17	<i>Hoxa9</i>
chr6	52209148	52210720	1.744	2.13E-11	<i>Hoxa13</i>
chr2	34227085	34227911	1.673	1.06E-15	<i>Pbx3</i>
chr16	92826076	92826431	1.512	9.67E-13	<i>Runx1</i>
chr6	52189788	52191356	1.486	1.20E-18	<i>Hoxa10</i>
chr15	61816547	61817382	1.399	9.91E-12	<i>Myc</i>
chr6	52195236	52196129	1.376	9.21E-08	<i>Hoxa11</i>
chr11	18918478	18919416	1.246	6.43E-12	<i>Meis1</i>
chr12	34642143	34643190	1.213	8.64E-07	<i>Twist1</i>






Supplementary Figure 4. Related to Figures 4; *dCas9-KRAB* mediated inhibition of *HOTTIP* lncRNA resulted in inhibition of active histone modifications and elevated repressive histone modifications in the posterior *HOXA* domain. (A, B) ChIP analysis of H3K9me2 **(A)** and H3K4me3 **(B)** enrichment at the *HOXA* locus compared WT control and *HOTTIP-dCas9-KRAB* MOLM13 clones. **(C)** RT-qPCR analysis of RNA retrieved by the complementary *HOTTIP*-tiling probes compared WT and *HOTTIP-dCas9-KRAB* inhibited MOLM13 cells. **(D)** ChIRP-qPCR analysis of the *HOTTIP* RNA enrichment at the *HOXA9* and other hematopoietic/leukemia specific genes compared WT and *HOTTIP-dCas9-KRAB* MOLM13 cells. **(E)** ChIRP-qPCR analysis of the *HOTTIP* RNA enrichment at the *HOXA9* and other hematopoietic/leukemia specific genes compared WT and *HOTTIP-dCas9-KRAB* OCI-AML3 cells carrying *NPM1^{C+}* mutation. **(F)** RT-qPCR analysis of *HOXA* gene expression in *MLL*-rearranged MOLM13 cells compared the WT control and the *HOTTIP-dCas9-KRAB* clones. **(G)** RT-qPCR validation of the key altered hematopoietic/leukemic genes identified by RNA-seq analysis compared among the WT control and two *HOTTIP-dCas9-KRAB* clones. **(H)** RT-qPCR analysis of *HOXA* gene expression in *NPM1^{C+}* mutated OCI-AML3 cells compared the WT control and the *HOTTIP-dCas9-KRAB* clones. **(I)** RT-qPCR validation of the key altered hematopoietic/leukemic genes identified by RNA-seq analysis compared among the WT control and *HOTTIP-KRAB* OCI-AML3 clones. **(J)** Proliferation curves of WT control and the *HOTTIP-dCas9-KRAB* MOLM13 clones were measured by cell viability count. **(K)** FACS analysis of cell cycle was carried out using propidium iodide staining of the WT control or the *HOTTIP-dCas9-KRAB* MOLM13 clones. **(L)** RT-qPCR analysis of the expression levels of *HOTTIP* and *HOXA* genes in primary AML patient BM cells carrying *MLL^{r+}* (LPP4), *NPM1^{C+}/FLT3-ITD⁺* (974), or *NPM1^C/FLT3-ITD⁺* (886). For statistics, data is presented as mean \pm SD from three to four independent experiments; *p<0.05; **p<0.01 by Student's t-test.


A




B




C










D



Supplementary Figure 5. Related to Figure 5; Reactivation of *HOTTIP* IncRNA rescues the posterior *HOXA* chromatin defects and gene expression in the *CBS7/9* boundary-disrupted AML cells. (A) Enrichment of upregulated target genes involved in JAK-STAT signaling and NOTCH signaling pathways in the *dCas9-VP-160* mediated *HOTTIP* activated *CBS7/9^{+/-}* MOLM13 clones compared to the *CBS7/9^{+/-}* MOLM13 cells as shown by GSEA. **(B)** Snap shot of ATAC-seq analysis of *RUNX1*(Left), *STAT5A* (Middle), and *TWIST1* (Right) loci compared among WT MOLM13 control, *CBS7/9^{+/-}* MOLM13 cells, and the *dCas9-VP-160* mediated *HOTTIP* activated *CBS7/9^{+/-}* MOLM13 clones. **(C)** ChIP-seq analysis of MLL1 recruitment in the Non-*HOX* targets compared among WT MOLM13 control, *CBS7/9^{+/-}* MOLM13 cells, and the *dCas9-VP-160* mediated *HOTTIP* activated *CBS7/9^{+/-}* MOLM13 clones. **(D)** ATAC-seq analysis of the alteration of chromatin accessibility in the *HOXB* locus compared among WT MOLM13 control, *CBS7/9^{+/-}* MOLM13 cells, and the *dCas9-VP-160* mediated *HOTTIP* activated *CBS7/9^{+/-}* MOLM13 clones.












Supplementary Figure 6. Related to Figure 6; *Hottip* lncRNA transgenic expression in hematopoietic compartment perturbs HSC function and results in AML-like disease.

(A) RT-qPCR analyses of *Hottip* RNA expression pattern of FACS-sorted different cell populations of WT mice. (B) Diagram of the *Vav1* promoter driven *Hottip* transgene strategy. (C) PCR based transgenic integrating location identification (TAIL) assay maps the *Vav1*-*Hottip* transgene integration site in the mouse chromosome 10. (D) RT-qPCR analysis of *Hottip* RNA expression in BM cells of WT and 2 lines of the *Hottip*-Tg mice. (E) RT-qPCR analysis of *Hottip* and *Hoxa* gene expression from purified LT-HSC and ST-HSC populations from WT control and *Hottip*-Tg mice. (F) Gross appearance of spleens of representative WT and two lines of *Hottip*-Tg mice (left). Showing is spleen/body weight ratio (right) for age matched WT (n = 7) and the *Hottip*-Tg (n = 10) mice. (G) FACS analysis of GMP, MEP and CMP populations within BM LK cells of representative young WT and *Hottip*-Tg mice (Top). Quantitation of the percentage of GMP, MEP and CMP cell populations in the Lin⁻ckit⁺Sca1⁻ cells of each genotype of mice are shown (bottom). n=7-10 mice/genotype. (H) FACS analysis and quantification of myeloid (Gr-1/Mac-1), erythroid (Ter119/CD71), B (B220/SSC) and T (CD4/CD8) cell populations in the BM of representative young WT and *Hottip*-Tg mice (8-week old). (I) The expression levels of *Hottip* in WT, *Hottip*-Tg, and *Hottip*^{homo}-Tg BM mononuclear cells (Left) as well as gross appearance of spleens and femurs of representative WT and moribund *Hottip*^{homo}-Tg mice (Right). (J) May-Giemsa stained PB smears and BM cytopins prepared from representative WT and moribund *Hottip*^{homo}-Tg mice. (K) FACS analysis of Lin⁻, LSK/LK, GMP/CMP, MEP, as well as LT-HSC/ST-HSC/MPP cell populations in the BM of representative young WT and *Hottip*^{homo}-Tg mice. (L) FACS analysis and quantification of myeloid (Gr-1/Mac-1), erythroid (Ter119), B (B220/SSC) and T (CD4/CD8) cell populations in the BM of representative young WT and *Hottip*-Tg mice (8-week old). (M) Quantitation of the total LSK and LK cell populations per femur of young WT (n=7), *Hottip*-Tg (n=10), and *Hottip*^{homo}-Tg (n=9) mice are shown. (N) Quantitation of the total LT-HSC, ST-HSC and MPP cell numbers per femur of young WT (n=7), *Hottip*-Tg (n=10), and *Hottip*^{homo}-Tg (n=9) mice are shown. (O) Quantitation of the total GMP, MEP, and CMP cell populations per femur of young WT (n=7), *Hottip*-Tg (n=10), and *Hottip*^{homo}-Tg (n=9) mice are shown. For statistics, data (Panels F-I, M-O) is presented as mean ± SD.



Table S3: Indel and snp variants analysis of whole exome sequencing of the *Hottip*-Tg AML mice. Related to Figure 6.






strelka method for exome-seq snp and indel analysis					
sample name #		indel	snp	indel_AA_change	snp_AA_change
<i>Hottip</i> -Tg mice	22	39	35	1	15
	39	81	50	3	14
	48	47	63	4	14
	51	49	76	2	27
	55	37	44	3	16
WT mice	69	54	52	4	14
	130	42	42	1	15
Recurrent mutation gene					
<i>Mroh2a</i>					





Supplementary Figure 7. Related to Figures 7; *Hottip* regulates self-renewal and proliferation of HSCs. (A-C) The expansion and proliferation potential of WT and *Hottip*-Tg HSC/HPCs were examined by culturing BM Lin⁻c-Kit⁺ cells in the presence of SCF, TPO, IL-3, G-CSF and EPO. No. of total cells (A), percent c-Kit⁺ cells and No. of CFU-Cs (B) in the progenies of Lin⁻c-Kit⁺ cells cultured for 7, 14 and 21 days were shown; representative histogram showed the c-Kit (CD117) expression in the cultures of WT and *Hottip*-Tg Lin⁻c-Kit⁺ cells for 14 days (C). (D) FACS analysis showing CD45.2 v.s. CD45.1 chimerism as well as their respective distribution of LSK/LK cell (within Lin⁻ cells) and lineage populations in the BM of representative mice receiving WT or *Hottip*-Tg BM cells. (E) Kinetic FACS analyses of CD45.2 (Donor) chimerisms in the PB of recipients (CD45.1) receiving WT or *Hottip*^{Homo}-Tg BM cells. (F) Images of May–Grunwald–Giemsa stained cytopsin preparations of BM cells from representative mice receiving WT or *Hottip*^{Homo}-Tg BM cells. Scale bar, 20 μm. (G) FACS analysis showing CD45.2 vs. CD45.1 chimerism and their respective lineage distribution of LSK/LK, GMP/CMP/MEP, LT-HSC/ST-HSC/MPP cell populations, as well as lineage distribution of myeloid, B and T (CD3/B220), immature myeloid in the BM of representative mice receiving WT or *Hottip*^{Homo}-Tg BM cells. For statistics, data (Panels A, B, and E) is presented as mean ± SD.





Supplementary Figure 8. Related to Figure 8; Transgenic expression of *Hottip* lincRNA remodels chromatin structure and alters hematopoietic transcription programs. (A) ChIRP-RT-qPCR analysis of the *Hottip* RNA enrichment at the *Hoxa7*, *Hoxa9* and other hematopoietic/leukemia specific genes in the purified BM HSCs (Including LT-HSCs and ST-HSCs) compared WT and *Hottip*-Tg mice. Data is presented as mean \pm SD from three to four independent experiments; * $p < 0.05$; ** $p < 0.01$ by Student's t-test. **(B)** Scatter blot of RNA-seq analysis of more than two folds of differentially expressed genes upon overexpression of *Hottip* lincRNA in BM ST-HSC populations of the *Hottip*-Tg mice as compared to WT control. **(C)** Heat map analysis for changed expression of representative genes associated with hematopoiesis and leukemogenesis upon *Hottip* overexpression in BM ST-HSC populations of the *Hottip* Tg mice as compared to WT control (Cutoff: Fold change ≥ 2 ; q value < 0.05). **(D)** ATAC-seq analysis of chromatin accessibility in the *Hoxa* locus compared the WT control and *Hottip* Tg mouse BM ST-HSCs. **(E)** ATAC-seq promoter density map of ST-HSCs sorted from WT and *Hottip* transgenic BM. Significant upregulated ATAC-seq promoter peaks correlate with GO terms of enriched pathways annotated by GREAT analysis compared between WT control and *Hottip* transgenic ST-HSCs (Top). Significant downregulated ATAC-seq promoter peaks correlate with GO terms of enriched pathways annotated by GREAT analysis compared between WT control and *Hottip* transgenic ST-HSCs (Bottom). **(F)** ATAC-seq analysis of *Hottip* trans-regulated genes important for hematopoiesis and leukemogenesis compared between WT control and the *Hottip*-Tg BM LT-HSC (Top) and ST-HSC (Bottom) populations. **(G)** ATAC-seq analysis of *Hoxb* locus compared between WT control and the *Hottip*-Tg BM LT-HSC (Top) and ST-HSC (Bottom) populations. **(H)** Expression of *HOTTIP* by RT-qPCR. 22 MLL-AML cell lines and primary samples and 7 non-MLL-AML primary samples were subjected to RT-qPCR, the *HOTTIP* expression of each sample were normalized to house-keeping gene GAPDH. The black bar represents the mean expression of each group. p value is determined by Students' t-test. **(I)** MLL-AML samples with high expression levels of *HOTTIP* were either treated with DMSO or ICG-001 (500 nM) and the cells were counted 5 days after treatment. The cell number of each sample was normalized to DMSO control (Left) or the cells were stained with 0.1% NBT and the differentiated cells were NBT-positive. The percentage of NBT-positive cells of each sample was normalized to DMSO control (Right). p value is determined by Students' t-test. **(J)** Primary MLL-AML samples that exhibit high levels of *HOTTIP* expression and Non-MLL samples with very low or silent *HOTTIP* expression levels were either treated with DMSO or ICG-001 (500 nM) and the long-term culture initiating cells (LTC-IC) frequency of each group were determined. The data was normalized with DMSO control which is set to 1. p value is determined by Students' t-test. **(K)** The human engraftment of bone marrow, spleen and liver of leukemic mice were determined by positive on human CD45 and CD33 comparing vehicle (Control; red; n=4) and ICG-001 (50 mg/Kg; green; n=5).